FDA commissioner nominee Overton rebuffs questions about Trump medical claims

WASHINGTON – In her opening remarks for the upcoming Senate committee hearing, nominee Heidi Overton to head the Food and Drug Administration (FDA) emphasizes the need for speed and efficiency within the agency. This, she claims, is essential to remain competitive with China's rapidly advancing biotechnology industry. In an exclusive preview of her statement, Overton asserts that she will adhere to President Trump's directive to "go fast" if confirmed to her new role.

She explains that stringent and cumbersome requirements imposed on innovative therapies by the FDA have led to significant investment flowing towards China, which has developed methods to expedite and reduce the costs of drug development. Overton is committed to carrying forward the administration's efforts to hasten the clinical trial process, initiated earlier this year through Operation Trailblazer.

She pledges to collaborate closely with dedicated professionals at the FDA to optimize all aspects of clinical trials and drug development, with the ultimate goal of accelerating the delivery of cures to patients and ensuring that every member of the FDA shares these objectives.